The agency issued final guidance on mobile apps, saying it will focus only on a subset that present the greatest risk to patients if they don't work correctly.
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
The months-old app seeks to become an all-in-one HCP tool and work on a 3.0 version is already in place.
Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results
Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director's Q&A
Sanofi named Connect & Coach as the winner of its 2013 Data Design Diabetes contest
Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M
Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
PricewaterhouseCoopers says consumers are talking healthcare, but not about the good stuff; Novartis shuffles 120 Texas jobs; 73% of STD app queries came from men last month; FDA is keeping very busy; and OgilvyCommonhealth hires a consumer head
Roche and Isis pair up for Huntingtons, Vital's prescription vision app gets approved, FDA approval revives maligned morning sickness drug, Gilead sends hep C therapy to regulators and Sanofi's emerging market exposure grabs attention.
Sanofi Pasteur scored a pharma first this past winter by offering "Shazam" technology as a way for viewers to interact with TV commercials for its Fluzone Intradermal influenza vaccine—and to find out where they could get the new shot.
Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
Taking a page from Sanofi, Shire is preparing to launch a developer challenge "to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood."
GSK, Pfizer and Shionogi's HIV medication to get its day in regulatory court; Philips finds that mobile and health are becoming inseparable.
Nature releases the Antibodypedia's seventh generation, Elsevier adds more board review apps, and how redefining "senior" may not save money in the long run
Novo Nordisk has launched a hemophilia app; and a report says the Chinese OTC market is going gangbusters
Sanofi's new chief medical officer takes a seat Jan. 1, Clinical Advisor launches a new app.
Sudler exec snags a lifetime Clio award, Merck leaves ALEC, and WebMD launches a pain app.
Lilly releases a diabetes app for caregivers, Merck KGaA to slash close to 1,100 jobs.
Statistics show medical professionals are migrating toward iPads. Now, one medical journal publisher says, advertisers have followed.
Chelsea Therapeutics clears house, trims focus; FDA grants 501 (k) status to a bluetooth blood pressure monitor.
Novo Nordisk expanded its motorsports initiative, while online firm Health Union launched a mobile app designed to help patients monitor migraines.
As of Monday, nurses will be able to tap into the Nursing Drug Handbook with an app, a first for the 32-year-old publication.
WebMD the Magazine is now part of the iPad app world.
Sanofi is re-upping its social media-driven Data Design Diabetes Innovation Challenge contest, which last year kicked up a wealth of innovative ideas and buzz for the price of $200,000 in prize money and a few salaries.
Everyday Health is going big on mobile, with 23 apps in six verticals, seeking advantage against its older competitor WebMD.
An Abbott iPhone app is drawing attention to the practice of compensating bloggers for app reviews, as some call into question the ethics of pay-for-play online PR.
Pharma investment in app development exploded last year, as companies branched out beyond diabetes, but industry spending on mobile is still dwarfed by other healthcare players, according to an Ernst & Young report.
Mylan's Dey Pharma launched MyEpiPen App, designed to help patients with severe allergies and their caregivers cope with episodes of anaphylaxis.